News
Zacks Investment Research on MSN1h
Regeneron Initial Data on Multiple Myeloma Drug EncouragingRegeneron Pharmaceuticals, Inc. REGN announced encouraging initial results from two cohorts of the early-stage study on ...
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...
4don MSN
It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly ...
Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...
We recently published a list of Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks. In this article, we ...
Not unlike Regeneron's acquisition of 23andMe, Predictive Oncology's AI-driven breakthroughs reflect a broader transformation ...
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback